Share on StockTwits

ABIOMED (NASDAQ:ABMD) CFO Robert Bowen unloaded 6,820 shares of the stock on the open market in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $21.11, for a total transaction of $143,970.20. Following the completion of the sale, the chief financial officer now directly owns 59,119 shares of the company’s stock, valued at approximately $1,248,002. The sale was disclosed in a legal filing with the SEC, which is available at this link.

ABIOMED (NASDAQ:ABMD) traded up 0.84% on Wednesday, hitting $21.71. 311,856 shares of the company’s stock traded hands. ABIOMED has a 52-week low of $18.15 and a 52-week high of $30.77. The stock’s 50-day moving average is $22.86 and its 200-day moving average is $26.29. The company has a market cap of $864.3 million and a P/E ratio of 119.61.

ABIOMED (NASDAQ:ABMD) last issued its quarterly earnings data on Thursday, May 1st. The company reported $0.09 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.08 by $0.01. The company had revenue of $50.40 million for the quarter, compared to the consensus estimate of $50.93 million. During the same quarter last year, the company posted $0.09 earnings per share. ABIOMED’s revenue was up 15.5% compared to the same quarter last year. On average, analysts predict that ABIOMED will post $0.30 earnings per share for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of ABIOMED in a research note on Thursday, May 15th. They now have a $23.00 price target on the stock. Separately, analysts at Leerink Swann initiated coverage on shares of ABIOMED in a research note on Monday, March 24th. They set an “outperform” rating and a $34.00 price target on the stock. Finally, analysts at BTIG Research upgraded shares of ABIOMED from a “neutral” rating to a “buy” rating in a research note on Friday, March 21st. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $26.83.

ABIOMED, Inc is a provider of mechanical circulatory support devices and offers a continuum of care to heart failure patients.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.